B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz; Leo I. Gordon; Jeremy S. Abramson; Ranjana H. Advani; Babis Andreadis; Nancy L. Bartlett; L. Elizabeth Budde; Paolo F. Caimi; Julie E. Chang; Beth Christian; Sven DeVos; Bhagirathbhai Dholaria; Luis E. Fayad; Thomas M. Habermann; Muhammad Saad Hamid; Francisco Hernandez-Ilizaliturri; Boyu Hu; Mark S. Kaminski; Yasmin Karimi; Christopher R. Kelsey; Rebecca King; Susan Krivacic; Ann S. LaCasce; Megan Lim; Marcus Messmer; Mayur Narkhede; Rachel Rabinovitch; Praveen Ramakrishnan; Erin Reid; Kenneth B. Roberts; Hayder Saeed; Stephen D. Smith; Jakub Svoboda; Lode J. Swinnen; Joseph Tuscano; Julie M. Vose; Mary A. Dwyer; Hema Sundar

doi:10.6004/jnccn.2023.0057

B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Julie E. Chang, Beth Christian, Sven DeVos, Bhagirathbhai Dholaria, Luis E. Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Boyu Hu, Mark S. Kaminski, Yasmin Karimi, Christopher R. KelseyRebecca King, Susan Krivacic, Ann S. LaCasce, Megan Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

Original language	English
Pages (from-to)	1118-1131
Number of pages	14
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	21
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2023.0057
State	Published - 2023

Access to Document

10.6004/jnccn.2023.0057

Cite this

Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, B., Bartlett, N. L., Budde, L. E., Caimi, P. F., Chang, J. E., Christian, B., DeVos, S., Dholaria, B., Fayad, L. E., Habermann, T. M., Hamid, M. S., Hernandez-Ilizaliturri, F., Hu, B., Kaminski, M. S., Karimi, Y., ... Sundar, H. (2023). B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 21(11), 1118-1131. https://doi.org/10.6004/jnccn.2023.0057

@article{3da3f0b5f2db4acd813bc9f43961e4f5,

title = "B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines",

abstract = "Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton{\textquoteright}s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.",

author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Babis Andreadis and Bartlett, {Nancy L.} and Budde, {L. Elizabeth} and Caimi, {Paolo F.} and Chang, {Julie E.} and Beth Christian and Sven DeVos and Bhagirathbhai Dholaria and Fayad, {Luis E.} and Habermann, {Thomas M.} and Hamid, {Muhammad Saad} and Francisco Hernandez-Ilizaliturri and Boyu Hu and Kaminski, {Mark S.} and Yasmin Karimi and Kelsey, {Christopher R.} and Rebecca King and Susan Krivacic and LaCasce, {Ann S.} and Megan Lim and Marcus Messmer and Mayur Narkhede and Rachel Rabinovitch and Praveen Ramakrishnan and Erin Reid and Roberts, {Kenneth B.} and Hayder Saeed and Smith, {Stephen D.} and Jakub Svoboda and Swinnen, {Lode J.} and Joseph Tuscano and Vose, {Julie M.} and Dwyer, {Mary A.} and Hema Sundar",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2023",

doi = "10.6004/jnccn.2023.0057",

language = "English",

volume = "21",

pages = "1118--1131",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "11",

}

Zelenetz, AD, Gordon, LI, Abramson, JS, Advani, RH, Andreadis, B, Bartlett, NL, Budde, LE, Caimi, PF, Chang, JE, Christian, B, DeVos, S, Dholaria, B, Fayad, LE, Habermann, TM, Hamid, MS, Hernandez-Ilizaliturri, F, Hu, B, Kaminski, MS, Karimi, Y, Kelsey, CR, King, R, Krivacic, S, LaCasce, AS, Lim, M, Messmer, M, Narkhede, M, Rabinovitch, R, Ramakrishnan, P, Reid, E, Roberts, KB, Saeed, H, Smith, SD, Svoboda, J, Swinnen, LJ, Tuscano, J, Vose, JM, Dwyer, MA & Sundar, H 2023, 'B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 21, no. 11, pp. 1118-1131. https://doi.org/10.6004/jnccn.2023.0057

TY - JOUR

T1 - B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, Babis

AU - Bartlett, Nancy L.

AU - Budde, L. Elizabeth

AU - Caimi, Paolo F.

AU - Chang, Julie E.

AU - Christian, Beth

AU - DeVos, Sven

AU - Dholaria, Bhagirathbhai

AU - Fayad, Luis E.

AU - Habermann, Thomas M.

AU - Hamid, Muhammad Saad

AU - Hernandez-Ilizaliturri, Francisco

AU - Hu, Boyu

AU - Kaminski, Mark S.

AU - Karimi, Yasmin

AU - Kelsey, Christopher R.

AU - King, Rebecca

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Lim, Megan

AU - Messmer, Marcus

AU - Narkhede, Mayur

AU - Rabinovitch, Rachel

AU - Ramakrishnan, Praveen

AU - Reid, Erin

AU - Roberts, Kenneth B.

AU - Saeed, Hayder

AU - Smith, Stephen D.

AU - Svoboda, Jakub

AU - Swinnen, Lode J.

AU - Tuscano, Joseph

AU - Vose, Julie M.

AU - Dwyer, Mary A.

AU - Sundar, Hema

PY - 2023

Y1 - 2023

N2 - Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

AB - Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

UR - http://www.scopus.com/inward/record.url?scp=85176388465&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2023.0057

DO - 10.6004/jnccn.2023.0057

M3 - Article

C2 - 37935098

AN - SCOPUS:85176388465

SN - 1540-1405

VL - 21

SP - 1118

EP - 1131

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this